Distinct actions of intermittent and sustained β-adrenoceptor stimulation on cardiac remodeling

XiaoWei Ma1, Yao Song, Chao Chen

  • 1Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.

Insights

Intermittent beta-adrenergic receptor (β-AR) stimulation with isoproterenol (ISO) causes more severe cardiac dysfunction and fibrosis than sustained exposure. This highlights the importance of experimental design in studying β-AR-induced cardiomyopathy.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Heart disease involves increased sympathetic activity and beta-adrenergic receptor (β-AR) stimulation, leading to pathological cardiac remodeling.
  • Isoproterenol (ISO) is commonly used to model β-AR-induced cardiac remodeling, but delivery method effects are unclear.

Purpose of the Study:

  • To compare the effects of intermittent versus sustained ISO administration on cardiac remodeling and function in mice.
  • To investigate the underlying molecular mechanisms, including fibrogenic factors.

Main Methods:

  • Mice received ISO (5 mg/kg/day) for 2 weeks via daily injection (intermittent) or osmotic minipump (sustained).
  • Cardiac function and remodeling assessed by echocardiography, micromanometry, and histology.
  • Protein and gene expression analyzed using Western blotting and qRT-PCR.

Main Results:

  • Both methods induced similar cardiac hypertrophy.
  • Intermittent ISO administration resulted in more severe ventricular systolic/diastolic dysfunction and myocardial fibrosis.
  • Increased expression of connective tissue growth factor (CTGF) and NADPH oxidase 4 (NOX4) observed with intermittent ISO.

Conclusions:

  • Intermittent β-AR stimulation leads to more severe cardiac dysfunction and fibrosis compared to sustained exposure.
  • Delivery mode significantly impacts experimental outcomes in β-AR-induced cardiomyopathy models.
  • Findings enhance understanding of β-AR roles in cardiac pathophysiology.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...